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• Cancer and chemotherapy developments
• Barriers requiring carriers
• Pharmaceutical nanolandscape




• Pharmacist, Chemist & Qualified Person
• Drugs into patients
• Range of research, formulation and product experience







• Established in 1983 – unique within UK
• Develop novel anti-cancer drugs selected by Cancer Research UK
• Antibodies – Alkylating Agents – Antisense




Drug Delivery in Cancer 
Chemotherapy
• Long history of delivery/targeting drugs to cancer
1958 – methotrexate conjugated to polyclonal antibody
• Early rationale
Alleviation of toxicity





Chen, Y., et.al., J.Cont.Rel., 1988;8;93-101
Microscopy Transferrin/Albumin/Polyaspartic acid microspheres
Introduction
Oral Nanoparticulate Systems
• Uptake of nanoparticles after gastro-intestinal administration
Jani, P., et.al., J.Pharm.Pharmacol., 1990;42;821-826
Jani, P., et.al., J.Pharm.Pharmacol., 1989;41;809-812
Introduction
Dawson, G.F., Halbert, G.W., Pharm.Res., 2000;17;1420-1425
Cancer and chemotherapy developments
Cancer Research
• Massive increase in biological understanding
• Imatinib – 2001 – targeted treatment
• Tumour heterogeneity
• Agile combination therapy
• Personalised therapy
Cancer and chemotherapy developments






Oral Bioavailability 98% 
Solubility sparingly
Oral Bioavailability 31% 
Solubility (1:2 DMSO:PBS) 0.3mg/ml
Oral Bioavailability 50% 
Cancer and chemotherapy developments
Intestinal Solubility Variation
• Impact of simulated gastrointestinal fluid composition



































































































“the most frequently reported attributes 
contributing to preference included convenience, 
ability to receive treatment at home, treatment 
schedule, and side effects.”
Oral administration
EeK, D., et.al., Patient Preference and Adherence 2016;10;1609-1621
Shih, Y-C.T., et.al., J.Clin.Oncol., 2015;33;2190-2196
Bioavailability


































Blanco, E., et.al., Nat.Biotechnol., 2015;33;941-951


































































Solid Capsular Liposome Niosome Simple Multiple Particulate Capsular





• Are they nanobased?
Drug dispersed in polymer – nano sized domains
Molecular dispersion or solution
• Route to increased kinetic solubility
• Systems variability possible
Nano-crystalline to amorphous
Polymer characteristics
• Extreme particle size reduction
Down to the molecule
NB also applicable for other systems





Jermain, S.V., et.al., Int.J.Pharm., 2018;535;379-392


























Perez-Herrero, E., et.al., Eur.J.PharmSci., 2015;93;52-79
Biswas, S et.al., Eur.J.PharmSci., 2016;83;184-202 Pharmaceutical nanolandscape




• Range of manufacturing techniques
Hot melt extrusion, solvent 
precipitation




• Solubility assistance only
Native drug
Martinez-Marcos, L., et.al., Int.J.Pharm., 2016;499;175-185
Solid dispersion
Dissolution of Albendazole
Amorphous, anthracyclines and taxanes
PAMAM-Doxorubicin dendrimer
Amorphous, anthracyclines and taxanes
Data from: Ke, W., et.al., J.Pharm.Sci., 2008;97;2208-2216
• Oral administration 20mg/kg in rat
• Particle size ≈ 4nm
• Doxorubicin
Cmax (µM) = 0.20
AUC (µg/mL)*h = 0.78
• Doxorubicin-PAMAM
Cmax (µM) = 7.63
AUC (µg/mL)*h = 247
• Doxorubicin IV 
Cmax (µM) ≈ 10




• Surface –polyethylene glycol or mannosamine
• Epirubicin @ 10mg/kg in rats
• Particle Size ≈ 250nm
Data from:   Tariq, M., et.al., Int.J.Pharm., 2016;501;18-31
Amorphous, anthracyclines and taxanes
Docetaxel microemulsion
• o/w microemulsion oral in rats
Capryol 90/cremophor/transcutol
• Droplet size ≈ 30nm
Yin, Y-M., et.al., J.Cont.Rel., 2009;140;86-94
iv 8mg/kg
po 10 mg/kg
Amorphous, anthracyclines and taxanes
Paclitaxel nanomicelle
• Dual functional system – in rats
Mucosal penetration & P-gp inhibition
• Particle size ≈ 250nm
Lian, H., et.al., Colloids and Surfaces B: Biointerfaces, 2017;155;429-439
po 15 mg/kg





Solvent, dialysis, sonication, centrifugation
• Issues of scale up
Working volume approx 10mL
• Control of complex polymers
Synthesis and impact on properties
• Stability
Chemical and physical
• Cost of goods



























Realistic values ≈ 10n
Conclusions
• Not yet - “set the heather alight!”
Struggling to break through
• Amorphous systems
Increasing acceptance – solubility only – or maybe not?
• Experimental promise – not realized clinically
• Not simply drug – but whole system
Efficacy, variability, biological interaction, manufacture and control
• Likely to arrive
Bioavailability improvement
• Watch this space
Recent Quote
Despite the demonstrated advantages by the preclinical studies, further studies on 
improved understanding of the interactions of SLNCs with biological tissues of the 
target site is necessary for efficient designing functional nanoparticles for clinical 
applications. Mu, H., Holm, R., Expert Opinion Drug Delivery 2018;15;771-785
Reviews
Tran, S., et.al., Clin.Trans.Med., 2017;6;44
Ventola, C.L., P&T., 2017;42;742-755
Thank you
• Funder – Cancer Research UK
• Collaborators
Many and varied
Local, national and international
• Organisers - Invitation
• You for listening
